MA50094A - Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol - Google Patents

Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol

Info

Publication number
MA50094A
MA50094A MA050094A MA50094A MA50094A MA 50094 A MA50094 A MA 50094A MA 050094 A MA050094 A MA 050094A MA 50094 A MA50094 A MA 50094A MA 50094 A MA50094 A MA 50094A
Authority
MA
Morocco
Prior art keywords
methods
related symptoms
sleep
treating
disturbances
Prior art date
Application number
MA050094A
Other languages
English (en)
Inventor
Denise Barbut
Michael Zasloff
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MA50094A publication Critical patent/MA50094A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050094A 2017-09-08 2018-09-05 Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol MA50094A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556164P 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
MA50094A true MA50094A (fr) 2020-07-15

Family

ID=65635152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050094A MA50094A (fr) 2017-09-08 2018-09-05 Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol

Country Status (4)

Country Link
US (2) US11083735B2 (fr)
EP (1) EP3678671A4 (fr)
MA (1) MA50094A (fr)
WO (1) WO2019050903A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50094A (fr) * 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
US20190298740A1 (en) * 2018-03-27 2019-10-03 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
WO2021025988A1 (fr) * 2019-08-02 2021-02-11 Enterin, Inc. Protocoles et schémas posologiques pour traitement à l'aminostérol
CA3224154A1 (fr) * 2021-06-27 2023-01-05 The Jackson Laboratory Determination visuelle d'etats de sommeil

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
CA2157594A1 (fr) 1993-03-10 1994-09-15 Leah L. Frye Derives steroidiques; compositions pharmaceutiques a base de ces derives et leur utilisation comme antibiotiques ou comme desinfectants
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
WO1996008270A2 (fr) 1994-09-13 1996-03-21 Magainin Pharmaceuticals Inc. Procede permettant d'inhiber la transmission de maladies sexuellement transmissibles a l'aide d'antimicrobiens du type magainin ou de composes de squalamine
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
ES2216049T3 (es) * 1995-06-07 2004-10-16 Genaera Corporation Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos.
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
JP2000510460A (ja) 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
AU773038B2 (en) 1998-08-12 2004-05-13 Genaera Corporation Aminosterol compounds and uses thereof
CA2606077C (fr) 2005-04-25 2013-07-09 Genaera Corporation Formes amorphes et polymorphes du sel de dilactate de squalamine
CA2632903C (fr) 2005-12-02 2015-11-24 Vianova Labs, Inc. Traitement du cancer et d'autres maladies
JP2009534391A (ja) * 2006-04-21 2009-09-24 ジェネーラ・コーポレーション 体重減少の誘発およびｐｔｐ１ｂの選択的阻害
CA2697744C (fr) * 2007-09-06 2016-06-14 Genaera Corporation Procede de traitement du diabete
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2013158970A2 (fr) * 2012-04-20 2013-10-24 Ohr Pharmaceutical Inc. Aminostéroïdes pour le traitement d'une maladie associée à ptp1b
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
MA50094A (fr) * 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol

Also Published As

Publication number Publication date
US11083735B2 (en) 2021-08-10
EP3678671A1 (fr) 2020-07-15
US20210338691A1 (en) 2021-11-04
US20190091241A1 (en) 2019-03-28
WO2019050903A1 (fr) 2019-03-14
EP3678671A4 (fr) 2022-12-07

Similar Documents

Publication Publication Date Title
MA50094A (fr) Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
IL271085A (en) Bacteria to treat disorders
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA46018A (fr) Activateurs d'édition du génome
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA51046A (fr) Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MA51315A (fr) Compositions et méthodes permettant de traiter des troubles du snc
MA46365A (fr) Méthodes de traitement de troubles mitochondriaux et métaboliques
IL259422A (en) Pharmaceutical contraceptives against stress-induced emotional disorders and their associated symptoms
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP2911664A4 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
EA033420B1 (ru) Производные индолин-2-она или пирролопиридин-2-она, обладающие антипсихотической активностью
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
MA43038A (fr) Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
MA54150A (fr) Compositions et méthodes de traitement de troubles dépendant des oestrogènes
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA47069A (fr) Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires
MA41689A (fr) Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
IL285708A (en) Imidazopyridinyl compounds and their uses in the treatment of neurodegenerative diseases